The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 Kit Research for Tissue Repair Pathways Hydration Room News & Media EVEXIAS Health Solutions BPC 157 + TB 500 Yooth Wellness Home Evexias Medical Center FDA Removes BPC 157, TB 500 and 10 More Peptides from Category 2 (April 2026)